Telix Pharmaceuticals announces licence agreement with Lilly for olaratumab
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Subscribe To Our Newsletter & Stay Updated